Chimeric Promoter Design for Tumor-Selective Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches face challenges in delivering transgenes effectively to tumors due to the weak transcriptional strength of intrinsic mammalian promoters like hTERT, which limits transgene expression and requires complex dual vector systems that are impractical for clinical use.
Innovation Solution
Development of novel chimeric promoters that combine a tissue-selective promoter sequence, such as hTERT, with a minimal viral promoter sequence, like miniCMV, to enhance promoter function and achieve high tumor specificity and transgene expression in a single vector.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the hTERT promoter is used for tumor-selective transgene expression, then tumor specificity is improved, but transcriptional strength and transgene expression level deteriorate
Solution Approach 1:
The patent merges the hTERT promoter (providing tumor specificity) with the CMV immediate-early promoter (providing strong transcriptional activity) to create a hybrid promoter. This combination allows the promoter to inherit both the tumor-selective expression capability of hTERT and the high transcriptional strength of CMV, thereby resolving the contradiction between specificity and expression level.
Solution Approach 2:
The hybrid promoter functions as a composite genetic element, combining functional domains from two different promoters (hTERT and CMV). Each promoter contributes specific functional properties: hTERT provides tumor-cell-specific transcriptional activation, while CMV provides robust basal transcriptional machinery recognition. The composite structure achieves both high expression and tumor selectivity.
2Reliability
If the hTERT promoter is used alone, then tumor selectivity is improved, but device complexity increases due to requirement of dual vector systems
Solution Approach 1:
The patent combines the tumor-selective function and the strong transcriptional function into a single hybrid promoter element, which can be delivered via a single vector system. This eliminates the need for complex dual vector systems that were previously required to achieve both tumor selectivity and adequate expression levels, thereby reducing system complexity while maintaining functionality.
3Productivity
If viral promoters like CMV are used for high transgene expression, then transcriptional strength is improved, but tumor selectivity deteriorates
Solution Approach 1:
The hybrid promoter merges the strong transcriptional activation capability of the CMV promoter with the tumor-specific regulatory elements of the hTERT promoter. The CMV portion ensures high transcriptional output, while the hTERT portion restricts this activity to tumor cells through tissue-specific transcription factors, thereby achieving both high expression and tumor selectivity simultaneously.
Data Source
AI summary
Promoters that include a tissue-selective promoter sequence and a second promoter sequence operatively coupled to the tissue-selective promoter sequence, wherein the second promoter sequence includes a minimal viral promoter sequence, are disclosed. Nucleic acids and compositions that include these promoter sequences are also disclosed. Also disclosed are methods of improving the function of a tissue-selective promoter, involving operatively coupling a tissue-selective promoter sequence with a second promoter sequence that includes a minimal viral promoter sequence. Also disclosed are methods of delivering a gene into a cell, methods of treating a subject with a hyperproliferative disease, and methods of imaging a cell that involve use of the novel promoter sequences set forth herein.